|
Importance of attenuating CXC-chemokine promoted angiogenesis as the mechanistic basis to enhanced Taxotere response in androgen-independent prostate cancer
Dr David Waugh & Dr Joe O'Sullivan, Queen's University, Belfast
|
|
Read more...
|
|
|
A double-blind, placebo-controlled, randomised phase II trial of selenium supplementation in men with localised prostate cancer on active surveillance
Dr Christopher Parker (Institute of Cancer Research) and Dr Margaret Rayman (University of Surrey)
|
|
Read more...
|
|
|
Inhibition of androgen signalling in prostate cancer using engineered repressors
Dr Charlotte Bevan, Dr Greg Brooke & Prof Simak Ali, Imperial College London
|
|
Read more...
|
|
|
Rational design of ErbB-3 based therapeutics for the treatment of prostate cancer
Prof Yosef Yarden & Dr Erez Bublil, The Weizmann Institute of Science, Israel
|
|
Read more...
|
|
|
Studying the role of NF-kB in prostate cancer - an integrated approach
Vladimir Yutkin & Eli Pikarsky, Hadassah-Hebrew University Medical Centre & Hebrew University-Hadassah Medical School, Israel
|
|
Read more...
|
|
|
